ACADIA PHARMACEUTICALS INC — Director's Dealing 2012

Nov 29, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2012-11-27

Reporting Person: Aasen Thomas H (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-11-27	Common Stock	G	33631	—	Disposed	28471	Direct
2012-11-27	Common Stock	G	33631	—	Acquired	35000	Indirect
2012-11-27	Common Stock	S	30900	$6.2414	Disposed	4100	Indirect
2012-11-28	Common Stock	M	5000	$1.08	Acquired	33471	Direct
2012-11-28	Common Stock	G	5000	—	Disposed	28471	Direct
2012-11-28	Common Stock	G	5000	—	Acquired	9100	Indirect
2012-11-28	Common Stock	S	9100	$5.2499	Disposed	0	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-11-28	Stock Option (right to buy)	$1.08	M	5000	Disposed	2013-09-07	Common Stock (5000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2011.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in mulitple transactions at prices ranging from $6.00 to $6.50 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.26 per share, inclusive.